This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Digging into the results from the phase 3 VIVID-1 clinical trial evaluating mirikizumab in patients with moderately to severely active Crohn's disease.
Ticker(s): LLYWho's the expert?
*CURRENTLY MANAGES 100 patients with NERD and 50 patients with ulcertive colitis*
Dr. Morris B. Silver practices Gastroenterology in Beverly Hills, California. Board certified since 1987, Dr. Silver assists patients suffering from diarrhea, constipation, abdominal pain, and rectal bleeding, as well as Inflammatory Bowel Disease and GERD. Services offered by Dr. Silver include colonoscopy and upper endoscopy. Dr. Silver earned his medical degree at the State University of N.Y. in Brooklyn, New York in 1984. He completed his residency at the Montefiore Hospital and Medical Center in the Bronx, NY in 1987. Dr. Silver went on to become a fellow in gastroenterology through a program at New York Medical College.
After practicing privately as a Gastroenterologist in New York from 1989 to 1990, Dr. Silver made the move to the West Coast. He has been practicing as a Gastroenterologist in California since 1990. During his career as a physician in California, Dr. Silver has worked in Orange County, Los Angeles, and Beverly Hills. When he is not in the office, he stays active with walking, exercising, and playing sports. He also loves spending time with his grandchildren.
Interview Goalto discuss the current standard of care and the potential of Eli Lilly's mirikizumab for treating active Crohn's disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
